The statistical software revolution in pharmaceutical development: challenges and opportunities in open source
Daniel Sabanés Bové(Dornier Flugzeugwerke (Germany)), Thomas Jaki(MRC Biostatistics Unit), Juliane Manitz(CGIAR), Burak K. Guünhan(Merck KGaA, Darmstadt (Germany)), Heidi Seibold(Bavarian Academy of Sciences and Humanities), Alessandro Gasparini(University of Leicester), Oliver Boix(Bayer (Germany)), Anna E. Jacob(Ludwig-Maximilians-Universität München), Sven Nahnsen(University of Tübingen), Sven Fillinger(University of Tübingen), Anne‐Laure Boulesteix(Zimmer Biomet (Netherlands))
Cited by 6
Related Papers
Bias in random forest variable importance measures: Illustrations, sources and a solution
|BMC Bioinformatics|2007|3.7k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Conditional variable importance for random forests
|BMC Bioinformatics|2008|3.3k
TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods
|BMJ|2024|2.8k
Overview of random forest methodology and practical guidance with emphasis on computational biology and bioinformatics
|Wiley Interdisciplinary Reviews Data Mining and Knowledge Discovery|2012|937